– Principal Repayments Delayed At Least Until January 1, 2022 – Repayment Delay and Recent ATM Activity Extends Cash Runway Substantially Through the First Quarter of 2022 DUBLIN, Ireland and FORT WASHINGTON, Pa., June 03, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative...
Category: News
Nabriva Announces Changes to its Board of Directors
DUBLIN, Ireland and FORT WASHINGTON, Pa., June 02, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Dr. Mark Corrigan and Lisa Dalton have joined the Company’s Board of Directors. In addition, after many years of service Dr....
Cidara to Present at Mycology 2021 Conference
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will virtually present highlights from pre-clinical through Phase 2 clinical trial data evaluating rezafungin, Cidara’s novel, once-weekly...
SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections
SCYNEXIS Announces FDA Approval of BREXAFEMME® (ibrexafungerp tablets) as the First and Only Oral Non-Azole Treatment for Vaginal Yeast Infections Approval of BREXAFEMME (ibrexafungerp) represents the first approved drug in a novel antifungal class in more than 20 years BREXAFEMME, a one-day oral treatment for vaginal yeast infection, is...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, June 01, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 6,000 ordinary shares of Nabriva Therapeutics as an inducement to two...
Iterum Therapeutics Provides Update on NDA Review
DUBLIN, Ireland and CHICAGO, May 27, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company participated...
Sinovant Sciences and Nabriva Therapeutics Announce Positive Topline Results from Phase 3 Trial of Lefamulin in Chinese Adults with Community Acquired Bacterial Pneumonia (CABP)
Lefamulin was shown to be non-inferior to moxifloxacin, with 76.8% of lefamulin-treated patients meeting the efficacy endpoint of Investigator Assessment of Clinical Response (IACR) at Test of Cure (TOC), compared to 71.4% of patients treated with moxifloxacin Lefamulin was generally safe and well-tolerated in Chinese adults Greater Chinese rights to lefamulin will be held by...
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 21, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the...
Summit Therapeutics Announces Preclinical Candidate and Associated CARB-X Funding Support for the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae, a CDC Urgent Threat and WHO Critical Priority
Cambridge, MA, May 18, 2021 – Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. Simultaneously, Summit has received an award from CARB-X to progress this candidate through preclinical development and Phase 1a...
SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update
SCYNEXIS Reports First Quarter 2021 Financial Results and Provides Corporate Update Secured non-dilutive funding of approximately $35 million thus far in 2021, including licensing payments from Hansoh Pharma, the first tranche from a term loan agreement with Hercules and Silicon Valley Bank, and the monetization of the...